



## Recent Advances in Asthma Research in a Multiomics Era

Guest Editors:

**Dr. Natalia Hernandez-Pacheco**

Department of Clinical Science  
and Education, Söderjukhuset,  
Karolinska Institutet,  
Sjukhusbacken 10, 118 83  
Stockholm, Sweden

**Dr. Esther Herrera-Luis**

Genomics and Health Group,  
Department of Biochemistry,  
Microbiology, Cell Biology and  
Genetics, Universidad de La  
Laguna, 38200 San Cristóbal de  
La Laguna, Spain

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editors

Dear Colleagues,

It is well known that asthma is a complex condition as the result of intricate interactions between numerous endogenous and exogenous factors. Among these, the important contribution of the individual's genetic composition and environmental exposures has been widely evidenced. Nonetheless, we are still far from understanding the complete picture of the molecular and cellular mechanisms underlying this disease, with the identification of novel disease biomarkers remaining necessary. These might contribute to the accurate diagnosis of asthma, effective treatment and disease control, early identification of those patients at higher risk for adulthood chronic airway disease, and the development of alternative preventive and therapeutic strategies in a personalized manner.

This Special Issue aims to focus on recent advances and applications of single- and combined omics approaches to the asthma field with a focus not only on disease susceptibility but also different asthma-related traits. Both original research and review articles are welcome.

Dr. Natalia Hernandez-Pacheco

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)